We are delighted to share the exciting news that Juana Lucia Flores-Candia, esteemed Board Member at leadXpro AG, is set to grace the stage at our forthcoming 2nd Ace Drug Discovery Summit (ADDS) at The Insurance Hall in London on the 20th and 21st of March 2024.Don’t miss the opportunity to be part of the […]
Latest developments, partnerships and scientific breakthroughs
Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets
Cumulus Oncology and leadXpro Announce Collaboration.
Resulting IP will be licensed into a newly created Cumulus company
Early drug discovery requires an interdisciplinary approach with a sophisticated interplay between empirical methods and rational design. Amongst the different therapeutic modalities, orally available small molecules are a major pillar for safe treatment of acute and chronic diseases.
RaQualia Pharma and leadXpro Announce Collaboration to Accelerate Drug Discovery on Intractable Membrane Protein Targets
In this collaboration, leadXpro will establish robust protocols and workflows to facilitate the rapid determination
Septerna Engages leadXpro to Discover Novel Binding Partners to GPCR Targets for use in Internal Drug Discovery Programs
During this engagement, leadXpro will use membrane proteins selected by Septerna to discover novel binding partners to…
To date, no structural information has been reported for the entire H+ activated GPCR family.
In collaboration with Merck/Serono, leadXpro confirmed the colocalization aspect of the mode of action of bintrafusp alfa using Cryo-Electron Microscopy
Listen to Michael Hennig’s talk at DDC 2022 about the impact of CGI and other biophysical methods on drug discovery for membrane proteins